Seismic Shift: Innovations in MRD Testing and Pathology will take place on November 6, 2026, as a live virtual session hosted by OncoDaily in partnership with Natera.

The webinar will explore the rapidly evolving role of Molecular Residual Disease (MRD) testing in cancer care, with a focus on technological advances, personalized ctDNA approaches, biomarker tracking, and the integration of modern testing into pathology workflows.

The session will examine how emerging MRD technologies are changing cancer monitoring and moving patient management toward more precise, individualized approaches. Participants will learn about advances in multimodal testing, high-sensitivity liquid biopsy methodologies, and digital platforms, while also exploring how modern assays can improve analytical sensitivity, specificity, and turnaround times.

The webinar will also address the practical side of implementing MRD testing, including specimen logistics, tissue stewardship, workflow optimization, and standardized reporting. Dr. Joe Lennerz will discuss the technological and clinical strategies driving this shift, with the session designed to help oncology and diagnostic professionals better understand how these developments can generate consistent and actionable insights for patient care.